PD168393

Research use only, not for human use.

PD168393 is an irreversible EGFR inhibitor (IC50: 0.70 nM), irreversibly alkylate Cys-773; inactive against PKC, FGFR, PDGFR, and insulin.

PD-168393 is a potent, cell-permeable, irreversible, ATP-competitive and selective inhibitor of EGF receptor (EGFR) tyrosine kinase activity (IC50 = 700 pM).

PD168393 inhibits ligand-dependent receptor phosphorylation and?inhibits EGF-induced tyrosine phosphorylation in A431 cells and Heregulin-induced tyrosine phosphorylation in MDA-MB-453 cells with IC50 values of 4.3? nM and 5.7? nM, respectively.

PD168393 (intraperitoneal injection; 58 mg/kg; once daily; days 10-14, 17-21, and 24-28) is effective?in vivo, and produces tumor growth inhibition of 115% after 15 days’ treatment in human epidermoid carcinoma xenografts in mice. Animal Model:A431 human epidermoid carcinoma grown as a xenograft in nude mice Dosage:58 mg/kg Administration:Intraperitoneal injection; 58 mg/kg; once daily; days 10-14, 17-21, and 24-28 Result:Suppressed the growth of human epidermoid carcinoma xenografts.

PD168393 | PD 168393 | PD-168393

Neuroscience

GluR

EGFR| FGFR| Insulin Receptor| PDGFR| PKC

Cancer

——

194423-15-9

369.22

C17H13BrN4O

>98% (HPLC)

DMSO : ≥ 30 mg/mL. 81.25 mM

C=CC(=O)Nc1cc2c(cc1)ncnc2Nc1cc(ccc1)Br

4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline

(-20℃)

With Ice Pack

≥ 2 years